The Pathogenic Mechanism of the Mycobacterium ulcerans Virulence Factor, Mycolactone, Depends on Blockade of Protein Translocation into the ER

PLoS Pathogens

Volumn 10, Issue 4, 2014, Pages

  Hall, Belinda S ^a   Hill, Kirsti ^b   McKenna, Michael ^c   Ogbechi, Joy ^a   High, Stephen ^c   Willis, Anne E ^d   Simmonds, Rachel E ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b BABRAHAM INSTITUTE   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d MRC TOXICOLOGY UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; INTERLEUKIN 6; MESSENGER RNA; MYCOLACTONE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VIRULENCE FACTOR; AUTACOID; CELL ADHESION MOLECULE; LIPOPOLYSACCHARIDE; MACROLIDE; PTGS2 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BACTERIAL TRANSLOCATION; BURULI ULCER; CELL ADHESION; CELL CULTURE; CELL FUNCTION; CELL STIMULATION; CELL SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; ENDOPLASMIC RETICULUM; GENE AMPLIFICATION; IMMUNE RESPONSE; IMMUNOCHEMISTRY; IN VITRO STUDY; MACROPHAGE; METABOLIC ACTIVITY ASSAY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSLATION; ANIMAL; CELL LINE; DRUG EFFECTS; METABOLISM; MICROBIOLOGY; MYCOBACTERIUM ULCERANS; PATHOGENICITY; PATHOLOGY; PROTEIN SYNTHESIS; SECRETION (PROCESS); TOXICITY;

ANIMALS; BURULI ULCER; CELL ADHESION MOLECULES; CELL LINE; CYCLOOXYGENASE 2; ENDOPLASMIC RETICULUM; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROLIDES; MICE; MYCOBACTERIUM ULCERANS; PROTEIN BIOSYNTHESIS; PROTEIN TRANSPORT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901374066     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004061     Document Type: Article

References (60)

1. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, et al. (1999) Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283: 854-857.
2. Demangel C, Stinear TP, Cole ST, (2009) Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nat Rev Microbiol 7: 50-60.
3. Stinear TP, Mve-Obiang A, Small PL, Frigui W, Pryor MJ, et al. (2004) Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A 101: 1345-1349.
4. Hall BS, Simmonds RE, (2013) Pleiotropic molecular effects of the Mycobacterium ulcerans virulence factor mycolactone underlying the cell death and immunosuppression seen in Buruli ulcer. Biochem Soc Trans 42: 177-183.
5. Simmonds RE, Lali FV, Smallie T, Small PL, Foxwell BM, (2009) Mycolactone inhibits monocyte cytokine production by a posttranscriptional mechanism. J Immunol 182: 2194-2202.
6. Guenin-Mace L, Carrette F, Asperti-Boursin F, Le Bon A, Caleechurn L, et al. (2011) Mycolactone impairs T cell homing by suppressing microRNA control of L-selectin expression. Proc Natl Acad Sci U S A 108: 12833-12838.
7. George KM, Pascopella L, Welty DM, Small PL, (2000) A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun 68: 877-883.
8. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, et al. (2013) Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest 123: 1501-1512.
9. Oliveira MS, Fraga AG, Torrado E, Castro AG, Pereira JP, et al. (2005) Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice. Infect Immun 73: 6299-6310.
10. Torrado E, Adusumilli S, Fraga AG, Small PL, Castro AG, et al. (2007) Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun 75: 3979-3988.
11. Hong H, Coutanceau E, Leclerc M, Caleechurn L, Leadlay PF, et al. (2008) Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs. PLoS Negl Trop Dis 2: e325.
12. Adusumilli S, Mve-Obiang A, Sparer T, Meyers W, Hayman J, et al. (2005) Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell Microbiol 7: 1295-1304.
13. Coutanceau E, Marsollier L, Brosch R, Perret E, Goossens P, et al. (2005) Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell Microbiol 7: 1187-1196.
14. Fraga AG, Cruz A, Martins TG, Torrado E, Saraiva M, et al. (2011) Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression. Infect Immun 79: 421-430.
15. Pahlevan AA, Wright DJ, Andrews C, George KM, Small PL, et al. (1999) The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. J Immunol 163: 3928-3935.
16. Coutanceau E, Decalf J, Martino A, Babon A, Winter N, et al. (2007) Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J Exp Med 204: 1395-1403.
17. Boulkroun S, Guenin-Mace L, Thoulouze MI, Monot M, Merckx A, et al. (2010) Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events. J Immunol 184: 1436-1444.
18. Phillips R, Sarfo FS, Guenin-Mace L, Decalf J, Wansbrough-Jones M, et al. (2009) Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease. J Infect Dis 200: 1675-1684.
19. Martins TG, Trigo G, Fraga AG, Gama JB, Longatto-Filho A, et al. (2012) Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection. PLoS Negl Trop Dis 6: e1925.
20. Schutte D, Um-Boock A, Mensah-Quainoo E, Itin P, Schmid P, et al. (2007) Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin. PLoS Negl Trop Dis 1: e2.
21. Anderson P, (2008) Post-transcriptional control of cytokine production. Nat Immunol 9: 353-359.
22. Azzam ME, Algranati ID, (1973) Mechanism of puromycin action: fate of ribosomes after release of nascent protein chains from polysomes. Proc Natl Acad Sci U S A 70: 3866-3869.
23. Ingolia NT, Lareau LF, Weissman JS, (2011) Ribosome profiling of mouse embryonic stem cells reveals the complexity and dynamics of mammalian proteomes. Cell 147: 789-802.
24. Rapoport TA, (2007) Protein translocation across the eukaryotic endoplasmic reticulum and bacterial plasma membranes. Nature 450: 663-669.
25. Lerner RS, Seiser RM, Zheng T, Lager PJ, Reedy MC, et al. (2003) Partitioning and translation of mRNAs encoding soluble proteins on membrane-bound ribosomes. RNA 9: 1123-1137.
26. Stephens SB, Dodd RD, Lerner RS, Pyhtila BM, Nicchitta CV, (2008) Analysis of mRNA partitioning between the cytosol and endoplasmic reticulum compartments of mammalian cells. Methods Mol Biol 419: 197-214.
27. Simmonds RE, Foxwell BM, (2008) Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. Rheumatology (Oxford) 47: 584-590.
28. Olszewski MB, Trzaska D, Knol EF, Adamczewska V, Dastych J, (2006) Efficient sorting of TNF-alpha to rodent mast cell granules is dependent on N-linked glycosylation. Eur J Immunol 36: 997-1008.
29. Besemer J, Harant H, Wang S, Oberhauser B, Marquardt K, et al. (2005) Selective inhibition of cotranslational translocation of vascular cell adhesion molecule 1. Nature 436: 290-293.
30. Garrison JL, Kunkel EJ, Hegde RS, Taunton J, (2005) A substrate-specific inhibitor of protein translocation into the endoplasmic reticulum. Nature 436: 285-289.
31. Cross BC, McKibbin C, Callan AC, Roboti P, Piacenti M, et al. (2009) Eeyarestatin I inhibits Sec61-mediated protein translocation at the endoplasmic reticulum. J Cell Sci 122: 4393-4400.
32. Snyder DS, Small PL, (2003) Uptake and cellular actions of mycolactone, a virulence determinant for Mycobacterium ulcerans. Microb Pathog 34: 91-101.
33. Rabu C, Schmid V, Schwappach B, High S, (2009) Biogenesis of tail-anchored proteins: the beginning for the end? J Cell Sci 122: 3605-3612.
34. Rajan RS, Tsumoto K, Tokunaga M, Tokunaga H, Kita Y, et al. (2011) Chemical and pharmacological chaperones: application for recombinant protein production and protein folding diseases. Curr Med Chem 18: 1-15.
35. Tokunaga F, Brostrom C, Koide T, Arvan P, (2000) Endoplasmic reticulum (ER)-associated degradation of misfolded N-linked glycoproteins is suppressed upon inhibition of ER mannosidase I. J Biol Chem 275: 40757-40764.
36. Mbonye UR, Wada M, Rieke CJ, Tang HY, Dewitt DL, et al. (2006) The 19-amino acid cassette of cyclooxygenase-2 mediates entry of the protein into the endoplasmic reticulum-associated degradation system. J Biol Chem 281: 35770-35778.
37. Patel NR, Bole M, Chen C, Hardin CC, Kho AT, et al. (2012) Cell elasticity determines macrophage function. PLoS One 7: e41024.
38. Van den Berg B, Clemons WM Jr, Collinson I, Modis Y, Hartmann E, et al. (2004) X-ray structure of a protein-conducting channel. Nature 427: 36-44.
39. Hegde RS, Keenan RJ, (2011) Tail-anchored membrane protein insertion into the endoplasmic reticulum. Nat Rev Mol Cell Biol 12: 787-798.
40. van de Veerdonk FL, Netea MG, Dinarello CA, Joosten LA, (2011) Inflammasome activation and IL-1beta and IL-18 processing during infection. Trends Immunol 32: 110-116.
41. Pelegrin P, Barroso-Gutierrez C, Surprenant A, (2008) P2X7 receptor differentially couples to distinct release pathways for IL-1beta in mouse macrophage. J Immunol 180: 7147-7157.
42. Liu Y, Law BK, Luesch H, (2009) Apratoxin a reversibly inhibits the secretory pathway by preventing cotranslational translocation. Mol Pharmacol 76: 91-104.
43. Wang Q, Shinkre BA, Lee JG, Weniger MA, Liu Y, et al. (2010) The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group. PLoS One 5: e15479.
44. McKibbin C, Mares A, Piacenti M, Williams H, Roboti P, et al. (2012) Inhibition of protein translocation at the endoplasmic reticulum promotes activation of the unfolded protein response. Biochem J 442: 639-648.
45. Luna A, Matas OB, Martinez-Menarguez JA, Mato E, Duran JM, et al. (2002) Regulation of protein transport from the Golgi complex to the endoplasmic reticulum by CDC42 and N-WASP. Mol Biol Cell 13: 866-879.
46. Thrasher AJ, Burns SO, (2010) WASP: a key immunological multitasker. Nat Rev Immunol 10: 182-192.
47. Gooding TM, Johnson PD, Campbell DE, Hayman JA, Hartland EL, et al. (2001) Immune response to infection with Mycobacterium ulcerans. Infect Immun 69: 1704-1707.
48. Gooding TM, Kemp AS, Robins-Browne RM, Smith M, Johnson PD, (2003) Acquired T-helper 1 lymphocyte anergy following infection with Mycobacterium ulcerans. Clin Infect Dis 36: 1076-1077.
49. Nienhuis WA, Stienstra Y, Abass KM, Tuah W, Thompson WA, et al. (2012) Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clin Infect Dis 54: 519-526.
50. Martins TG, Gama JB, Fraga AG, Saraiva M, Silva MT, et al. (2012) Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection. PLoS One 7: e32740.
51. Sarfo FS, Converse PJ, Almeida DV, Zhang J, Robinson C, et al. (2013) Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease. PLoS Negl Trop Dis 7: e2101.
52. Almeida DV, Converse PJ, Li SY, Tyagi S, Nuermberger EL, et al. (2013) Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease. PLoS Negl Trop Dis 7: e2085.
53. Yuhas Y, Berent E, Ashkenazi S, (2011) Effect of rifampin on production of inflammatory mediators in HepG2 liver epithelial cells. Antimicrob Agents Chemother 55: 5541-5546.
54. Pahlevan AA, Wright DJ, Bradley L, Smith C, Foxwell BM, (2002) Potential of rifamides to inhibit TNF-induced NF-kappaB activation. J Antimicrob Chemother 49: 531-534.
55. Song F, Fidanze S, Benowitz AB, Kishi Y, (2002) Total synthesis of the mycolactones. Org Lett 4: 647-650.
56. Johannes G, Sarnow P, (1998) Cap-independent polysomal association of natural mRNAs encoding c-myc, BiP, and eIF4G conferred by internal ribosome entry sites. RNA 4: 1500-1513.
57. Powley IR, Kondrashov A, Young LA, Dobbyn HC, Hill K, et al. (2009) Translational reprogramming following UVB irradiation is mediated by DNA-PKcs and allows selective recruitment to the polysomes of mRNAs encoding DNA repair enzymes. Genes Dev 23: 1207-1220.
58. Walter P, Blobel G, (1983) Preparation of microsomal membranes for cotranslational protein translocation. Methods Enzymol 96: 84-93.
59. Wilson R, Allen AJ, Oliver J, Brookman JL, High S, et al. (1995) The translocation, folding, assembly and redox-dependent degradation of secretory and membrane proteins in semi-permeabilized mammalian cells. Biochem J 307 (Pt 3):: 679-687.
60. Shekar PC, Goel S, Rani SD, Sarathi DP, Alex JL, et al. (2006) kappa-casein-deficient mice fail to lactate. Proc Natl Acad Sci U S A 103: 8000-8005.